TTNP: Titan Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TTNP: Titan Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 3.02
Enterprise Value ($M) -0.38
Book Value ($M) 3.23
Book Value / Share 3.53
Price / Book 0.93
NCAV ($M) 3.23
NCAV / Share 3.53
Price / NCAV 0.93

Profitability (mra)
Return on Invested Capital (ROIC) -1.82
Return on Assets (ROA) -0.73
Return on Equity (ROE) -0.89

Liquidity (mrq)
Quick Ratio 9.71
Current Ratio 9.71

Balance Sheet (mrq) ($M)
Current Assets 3.60
Assets 3.60
Liabilities 0.37
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
08-21 13D/A Sire Group Ltd. 14.10 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-01-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. ☐ TRANSITION REPORT PURSUAN
2024-08-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. ☐ TRANSITION REPORT PURSUANT TO
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. ☐ TRANSITION REPORT PURSUANT TO
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 545 2,559 21.30
2025-02-03 1,261 13,380 9.42
2025-01-31 943 7,748 12.17
2025-01-30 1,891 6,258 30.22

(click for more detail)

Similar Companies
TNXP – Tonix Pharmaceuticals Holding Corp. TPST – Tempest Therapeutics, Inc.
TRAW – Traws Pharma, Inc. UNCY – Unicycive Therapeutics, Inc.
UPC – Universe Pharmaceuticals INC


Financial data and stock pages provided by
Fintel.io

Finpedia: Titan Pharmaceuticals